July 22 (Reuters) - Pfizer said on Wednesday the U.S. Food and Drug Administration has granted priority review to its ...
Pfizer said Wednesday the Food and Drug Administration accepted for priority review its supplemental application seeking to expand the use of its prostate cancer treatment Talzenna in combination with ...
A noninvasive DNA blood test can identify patients with metastatic castration-resistant prostate cancer (mCRPC) who are most ...
In this long-term follow-up to the phase 2 ARTO trial, researchers analyzed survival outcomes in patients with CRPC treated with metastasis-directed therapy.
A noninvasive DNA blood test can identify metastatic castration-resistant prostate cancer (mCRPC) patients who are most ...
Recently published Metastatic Castration-resistant Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, metastatic castration-resistant ...
Dr. Rohan Garje shares the updated recommendations for the ASCO guideline on systemic therapy for patients with metastatic castration-resistant prostate cancer. He discusses the systemic therapy ...
Nubeqa (darolutamide) received FDA approval for metastatic castration-sensitive prostate cancer, showing significant improvement in radiographic progression-free survival. The ARANOTE trial involved ...
A new editorial paper titled "Using early on-treatment circulating tumor DNA measurements as response assessment in metastatic castration resistant prostate cancer" has been published in Oncotarget.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results